NO20093536L - Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab - Google Patents

Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab

Info

Publication number
NO20093536L
NO20093536L NO20093536A NO20093536A NO20093536L NO 20093536 L NO20093536 L NO 20093536L NO 20093536 A NO20093536 A NO 20093536A NO 20093536 A NO20093536 A NO 20093536A NO 20093536 L NO20093536 L NO 20093536L
Authority
NO
Norway
Prior art keywords
vinflunine
trastuzumab
cancer therapy
therapy including
combination cancer
Prior art date
Application number
NO20093536A
Other languages
English (en)
Norwegian (no)
Inventor
Bart Vanhauwere
Marie-Claire Pinel
Francois-Michel Delgado
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38353425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20093536(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20093536L publication Critical patent/NO20093536L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20093536A 2007-05-31 2009-12-16 Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab NO20093536L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290679A EP1997534A1 (en) 2007-05-31 2007-05-31 Cancer treatment combination therapy comprising vinflunine and trastuzumab
PCT/EP2008/056620 WO2008145697A1 (en) 2007-05-31 2008-05-29 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Publications (1)

Publication Number Publication Date
NO20093536L true NO20093536L (no) 2009-12-16

Family

ID=38353425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093536A NO20093536L (no) 2007-05-31 2009-12-16 Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab

Country Status (18)

Country Link
US (1) US20100196363A1 (ko)
EP (2) EP1997534A1 (ko)
JP (1) JP2010528091A (ko)
KR (1) KR20100017752A (ko)
CN (1) CN101687104A (ko)
AR (1) AR066778A1 (ko)
AU (1) AU2008257555A1 (ko)
BR (1) BRPI0812280A2 (ko)
CA (1) CA2689664A1 (ko)
CL (1) CL2008001589A1 (ko)
IL (1) IL202393A0 (ko)
MX (1) MX2009012874A (ko)
NO (1) NO20093536L (ko)
RU (1) RU2009146882A (ko)
TN (1) TN2009000490A1 (ko)
TW (1) TW200908976A (ko)
WO (1) WO2008145697A1 (ko)
ZA (1) ZA200908247B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
WO2018007554A1 (en) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
MA47313B1 (fr) 2017-01-17 2020-12-31 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
ZA200908247B (en) 2010-10-27
US20100196363A1 (en) 2010-08-05
WO2008145697A1 (en) 2008-12-04
AR066778A1 (es) 2009-09-09
IL202393A0 (en) 2010-06-30
RU2009146882A (ru) 2011-07-10
EP2164573A1 (en) 2010-03-24
CL2008001589A1 (es) 2009-03-06
TW200908976A (en) 2009-03-01
BRPI0812280A2 (pt) 2014-11-18
CN101687104A (zh) 2010-03-31
AU2008257555A1 (en) 2008-12-04
CA2689664A1 (en) 2008-12-04
JP2010528091A (ja) 2010-08-19
KR20100017752A (ko) 2010-02-16
TN2009000490A1 (en) 2011-03-31
EP1997534A1 (en) 2008-12-03
MX2009012874A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
NO20093536L (no) Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
NO20092637L (no) Fremgangsmater for behandling
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201170521A1 (ru) Новые соединения
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
BRPI0821779A2 (pt) tratamento terapêutico de câncer
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA201170834A1 (ru) Соединения, пригодные для ингибирования chk1
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
EP2165715A4 (en) THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER
EA201370071A1 (ru) Способы и композиции для лечения рака легких
EA201001865A1 (ru) Противовоспалительные агенты
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application